Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 2/20 | 0.39 |
| ▸ | PPARA | Q07869 | 2/20 | 0.39 |
| ▸ | PPARD | Q03181 | 1/20 | 0.39 |
| ▸ | FAAH | O00519 | 2/20 | 0.39 |
| ▸ | FFAR4 | Q5NUL3 | 3/20 | 0.39 |
| ▸ | ALOX5 | P09917 | 3/20 | 0.38 |
| ▸ | FNTA | P49354 | 1/20 | 0.38 |
| ▸ | FNTB | P49356 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6405296 | 1.00 | PPARG (0.39) | PPARGPPARAPPARDFAAHFFAR4 | |
| SCHEMBL6408673 | 0.91 | ALOX5 (0.44) | PPARGPPARAFAAHFFAR4ALOX5 | |
| SCHEMBL6407685 | 0.91 | ALOX5 (0.44) | PPARGPPARAFAAHFFAR4ALOX5 | |
| SCHEMBL6409786 | 0.83 | FFAR4 (0.40) | FFAR4 | |
| SCHEMBL6404991 | 0.83 | FFAR4 (0.40) | FFAR4 | |
| SCHEMBL6409075 | 0.82 | PTGS1 (0.39) | PPARGPPARAPPARD | |
| SCHEMBL6412079 | 0.82 | PTGS1 (0.39) | PPARGPPARAPPARD | |
| SCHEMBL6405230 | 0.81 | MMP3 (0.40) | FAAHFFAR4 | |
| SCHEMBL6406846 | 0.81 | MMP3 (0.40) | FAAHFFAR4 | |
| SCHEMBL6410142 | 0.81 | PDE4A (0.43) | PPARAPPARDFFAR4ALOX5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6855730-B2 | 3-methylidenyl-2-indolinone modulators of protein kinase | SUGEN, INC. (US) | 2005-02-15 | — | — | US | disclosed |
| US-20050010050-A1 | Dihydrobenzopyrans, dihydrobenzothiopyrans, and tetrahydroquinolines for the treatment of COX-2-mediated disorders | G.D. SEARLE & CO. (US) | 2005-01-13 | — | — | US | disclosed |
| US-6822102-B2 | COMPOUNDS SUCH AS (2S,3R)-6,8-DICHLORO-3,4-DIHYDRO-2-(TRIFLUOROMETHYL)-2H-1-BENZOPYRAN-3 -CARBOXYLIC ACID, USED AS ANTIINFLAMMATORY, ANTIARTHRITIC, ANTICARCINOGENIC AGENTS OR ANALGESICS | PHARMACIA CORPORATION | 2004-11-23 | — | — | US | disclosed |
| EP-1274700-B1 | DIHYDROBENZOPYRANS, DIHYDROBENZOTHIOPYRANS, AND TETRAHYDROQUINOLINES FOR THE TREATMENT OF COX-2-MEDIATED DISORDERS | PHARMACIA CORP (US) | 2004-11-17 | — | — | EP | disclosed |
| US-20040024010-A1 | 3-methylidenyl-2-indolinone modulators of protein kinase | SUGEN, INC. | 2004-02-05 | — | — | US | disclosed |
| US-20030232844-A1 | Dihydrobenzopyrans, dihydrobenzothiopyrans, and tetrahydroquinolines for the treatment of cox-2 mediated disorders | PHARMACIA CORPORATION | 2003-12-18 | — | — | US | disclosed |
| US-6531502-B1 | Antitumor | SUGEN, INC. | 2003-03-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040024010-A1 | 3-methylidenyl-2-indolinone modulators of protein kinase | DMPK, MAP4K3, MAP3K20 | PPARG 3562/4885PPARA 4163/4885PPARD 3216/4885 |
| US-20050010050-A1 | Dihydrobenzopyrans, dihydrobenzothiopyrans, and tetrahydroquinolines for the treatment of COX-2-mediated disorders | PTGS2, PTGES2, PTGER2 | PPARG 960/4885PPARA 1530/4885PPARD 1976/4885 |
| US-20030232844-A1 | Dihydrobenzopyrans, dihydrobenzothiopyrans, and tetrahydroquinolines for the treatment of cox-2 mediated disorders | PTGS2, PTGS1, PTGES2 | PPARG 1281/4885PPARA 1812/4885PPARD 2255/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.